Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Arrowhead Research  /  GRTS (mRNA) Gritstone bio inc.

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Arrowhead Pharmaceuticals OTC:ARWR.Q, US04280A1007

  • 24,770 17 mei 2024 22:00
  • -0,230 (-0,92%) Dagrange 24,567 - 25,640
  • 710.610 Gem. (3M) 1,2M

GRTS (mRNA) Gritstone bio inc.

290 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 15 »» | Laatste | Omlaag ↓
  2. forum rang 5 Piddy 25 februari 2024 12:13
    Zo'n twee weekjes voor de resultaten ivm Granith.

    Daarna gehele resultaten waarschijnlijk op ASCO
    Kan wel nog eens stoploss raid zijn rond de daily MA200 van $1,98, tot misschien max $1,92 of lager voor enkele minuten...
    Anderzijds zit er praktisch niks tussen de $2,50 en $5,15

    Vermoedelijk zien we alles wel heel even passeren.
    Rustig blijven zitten of bijkopen op laagte is hier de boodschap.

    GRANITE : geïndividualiseerd neoantigeenvaccinprogramma

    Ons eerste oncologieprogramma, GRANITE, is een geïndividualiseerde op neoantigeen gebaseerde immunotherapie. GRANITE wordt geëvalueerd in een fase 2/3-studie waarin GRANITE wordt geëvalueerd als onderhoudsbehandeling bij patiënten met nieuw gediagnosticeerde, gemetastaseerde microsatelliet-stabiele colorectale kanker (MSS-CRC) die de inductietherapie met FOLFOX-bevacizumab hebben afgerond. GRANITE kreeg van de Amerikaanse Food and Drug Administration de Fast Track-status voor de behandeling van MSS-CRC.

    Voor elke patiënt begint onze geïndividualiseerde immunotherapie met een routinematige klinische biopsie. Vervolgens sequencen we het tumormonster intern en passen we ons eigen EDGE™-platform toe om een ??reeks voorspelde patiëntspecifieke neoantigenen af ??te leiden die waarschijnlijk op de tumor van de patiënt zullen worden gepresenteerd. Met behulp van deze voorspelde neoantigenen zullen we vervolgens een geïndividualiseerde immunotherapie ontwerpen die de relevante neoantigenen bevat, toe te dienen via eenvoudige intramusculaire injectie. We zijn van plan de immunotherapie te leveren in een gemeenschapsoncologische setting waar de grote meerderheid van de kankerpatiënten wordt behandeld.
  5. forum rang 5 Piddy 25 februari 2024 19:56
    Gritstone Bio EDGE: The AI Revolution in Personalized Cancer Vaccines

    Feb 25
    Written By David Stone

    Imagine a world where cancer treatment is not a one-size-fits-all approach but is as unique as the DNA of the person fighting the disease. This is not a script from a sci-fi movie but the reality we're stepping into, thanks to the marvels of artificial intelligence (AI) in healthcare, particularly in the development of personalized cancer vaccines. As I sit down to pen this exploration, it's impossible not to notice the buzz around AI and its influence across sectors, especially in the stock market. For instance, NVIDIA ($NVDA), a company at the forefront of AI technology, has seen its stock price skyrocket from $232 to $788 in just a year, showcasing the economic optimism surrounding AI innovations.

    This surge is not just a fleeting trend but a testament to the transformative power of AI, especially in the medical field. Companies like Gritstone Bio are harnessing AI to spearhead the development of personalized cancer vaccines, offering a beacon of hope for millions. The company's EDGE™ platform is a shining example of how AI can revolutionize cancer treatment by tailoring vaccines to the individual's genetic makeup, potentially turning the tide in the fight against this formidable foe.

    Let's dive deeper into this groundbreaking technology and the company leading this charge, unraveling the layers of science, technology, and innovation that make personalized cancer vaccines not just a possibility but a reality.

    Understanding Gritstone Bio and Its Mission

    Gritstone Bio stands at the forefront of a revolution in cancer treatment, wielding the power of AI to unlock the potential of personalized medicine. At its core, Gritstone's mission is ambitious yet simple: to develop groundbreaking immunotherapies that harness the body's own immune system to fight cancer and infectious diseases. This mission is not just a lofty goal but a reflection of a profound understanding that the key to combating these diseases lies in the unique genetic landscape of each individual.

    The company's approach is rooted in the science of immunotherapy, which aims to stimulate the patient's immune system to recognize and destroy tumors or virally infected cells. One of the fundamental challenges in this field is the identification of antigens—substances that can trigger an immune response—specifically those that can effectively target and kill cancer cells without harming healthy tissue. Gritstone's solution to this challenge is its proprietary EDGE platform, an AI-driven technology designed to accurately identify T cell targets. This platform is not just a technological marvel; it represents a paradigm shift in how we approach the development of cancer vaccines.

    Gritstone's vision extends beyond the current horizon, aiming to extend the benefits of immunotherapy to a broader patient population. By developing personalized cancer vaccines, the company hopes to deliver treatments that are not only effective but also tailored to the genetic profile of each patient, offering a new level of precision in cancer care.

    In essence, Gritstone Bio's mission encapsulates the promise of AI in healthcare: to leverage technology to uncover novel treatments that are as individual as the patients they aim to cure.

    The Science of Personalized Cancer Vaccines
    Diving into the heart of personalized cancer vaccines, we find ourselves in a world where the battle against cancer gets a tailor-made armor. The principle behind these vaccines is as fascinating as it is complex. At the center of this innovation is the understanding of tumor antigens, small proteins on the surface of tumor cells that act as targets for T cell-mediated destruction. But not all antigens are created equal. The landscape is diverse, ranging from antigens specific to certain cell types to those that are unique to the tumor itself, known as neoantigens.

    Gritstone Bio's approach leverages this complexity in a strategic manner. The company focuses on identifying these neoantigens, particularly those arising from mutations unique to each patient's tumor. These mutations are the body's own typos in the DNA sequence, creating unique markers that can be targeted by the immune system. However, the real challenge lies not just in identifying these markers but in predicting which ones will effectively elicit a strong immune response.

    Gritstone's EDGE platform doesn't merely sift through genetic data, it uses advanced algorithms and machine learning to predict which mutations are likely to produce the most potent neoantigens. This process involves analyzing millions of data points from tumor and normal tissue samples, allowing Gritstone to pinpoint the neoantigens most likely to be presented on the tumor cell surface. This precision is not just about targeting the right markers; it's about ensuring that the immune system can recognize and attack them efficiently.

    But Gritstone's innovation doesn't stop at identification. The company is also pioneering in how these neoantigens are delivered to the patient's immune system. Using cutting-edge delivery systems, Gritstone aims to stimulate the immune system to generate T cells and neutralizing antibodies against these targets. This approach not only aims to attack existing cancer cells but also to train the immune system to recognize and combat any future occurrences, offering a glimpse into a future where cancer vaccines are personalized, potent, and hopefully prophylactic.

    EDGE represents a shift from the blunt tools of traditional chemotherapy to the precision-guided missiles of immunotherapy, targeting the disease at its genetic roots with minimal collateral damage. This is the promise of Gritstone Bio's research: a future where cancer treatment is not just about surviving but thriving, with therapies tailored to the genetic fabric of each individual.
  6. forum rang 5 Piddy 25 februari 2024 19:57
    EDGE™: The AI Powerhouse Behind Gritstone's Innovations

    The magic of EDGE lies in its ability to sift through the genetic chaos of cancer, identifying those rare mutations that can serve as neoantigens. These neoantigens are the rogue signals that, once recognized by the immune system, can trigger a targeted attack on the cancer cells. The platform's prowess is not just in the identification but in the prediction of which mutations are likely to result in the most effective neoantigens. This involves an intricate dance of bioinformatics, with EDGE leveraging a novel integrated neural network model. This AI model is trained on millions of data points from hundreds of tumor and normal tissue samples across diverse ancestries, enabling it to predict with unprecedented accuracy which mutations will generate tumor-specific neoantigens most likely to be presented on the tumor cell surface.

    What sets EDGE apart is not just its predictive accuracy but its practical impact. By identifying the most promising neoantigens, Gritstone can create personalized vaccines that instruct the immune system to recognize and attack these specific targets. This approach represents a significant leap forward from traditional cancer treatments, offering a more targeted, effective, and potentially less toxic alternative.

    But EDGE's capabilities extend beyond cancer. The platform also holds promise in the fight against infectious diseases, using similar principles to identify key viral protein fragments that can drive strong T cell responses. This versatility showcases the broad potential of AI in healthcare, where technology can adapt and evolve in response to diverse medical challenges.

    The development and refinement of the EDGE platform reflect a broader trend in medicine: the shift towards precision and personalization. In this new era, treatments are increasingly designed to match the unique genetic profile of each patient, offering hope for more effective and tailored therapies. Gritstone's EDGE platform is at the forefront of this revolution, harnessing the power of AI to unlock new possibilities in the fight against cancer and beyond.

    From Lab to Clinic: Gritstone's Vaccine Pipeline
    At the heart of this pipeline are two key classes of tumor-specific neoantigen product candidates: GRANITE and SLATE. GRANITE represents Gritstone's individualized immunotherapy program, designed for patients with neoantigens arising from patient-specific mutations. This bespoke approach is akin to crafting a custom suit, tailored to fit the unique genetic mutations of an individual's tumor, potentially driving a potent immune response tailored to each patient's cancer.

    On the other hand, SLATE embodies Gritstone's investigational off-the-shelf immunotherapy program. This approach targets neoantigens derived from common driver mutations shared among certain cancer patients. Imagine this as a ready-to-wear line, offering a more generalized but still highly targeted option for cancer treatment, based on shared genetic characteristics among tumors.

    Both GRANITE and SLATE are emblematic of the broader strategy in cancer immunotherapy: to harness the body's own defenses in a highly specific attack against cancer cells, minimizing harm to healthy tissues and potentially improving patient outcomes. This strategy is underpinned by the meticulous identification and prediction capabilities of the EDGE platform, ensuring that the vaccines target the most promising neoantigens.

    The move from lab to clinic is not merely a step but a giant leap, involving rigorous clinical trials designed to test the safety, efficacy, and optimal usage of these vaccines. These trials are the proving grounds for Gritstone's innovations, where the theoretical potential of personalized cancer vaccines faces the stringent tests of real-world application. Success in these trials could herald a new era in cancer treatment, one where the disease is combated not with the blunt instruments of traditional chemotherapy but with the precision of immunotherapy, tailored to the genetic makeup of each tumor.

    Gritstone's vaccine pipeline represents the cutting edge of cancer treatment, a vivid illustration of the promise held by personalized medicine. As these vaccines progress through clinical trials, they offer a glimpse into a future where cancer treatment is not only more effective but also more personal, aligning with the unique genetic landscape of each patient.
  7. forum rang 5 Piddy 25 februari 2024 19:57
    Beyond Cancer: Tackling Infectious Diseases with BARDA's Support

    Gritstone Bio's innovative approach to combating infectious diseases reached a new milestone with the support of the Biomedical Advanced Research and Development Authority (BARDA). In a significant endorsement of Gritstone's technology and potential, BARDA awarded the company a contract valued at up to $433 million to conduct a Phase IIb clinical trial of its self-amplifying mRNA (samRNA) COVID-19 vaccine candidate, marking a pivotal step in the fight against the pandemic.

    This contract, under the auspices of the Department of Health and Human Services, signals a substantial investment in developing next-generation vaccines with the potential to offer broader, more durable protection against COVID-19 and its variants. Gritstone's samRNA vaccine aims to induce robust neutralizing antibody and T cell-based immunity, addressing limitations observed in first-generation COVID-19 vaccines, particularly in terms of breadth and durability of protection.

    Gritstone's CORAL program, which encompasses this vaccine development, represents a comprehensive effort to harness self-amplifying mRNA technology and novel immunogens targeting both the Spike protein and additional viral targets. This "Spike plus" strategy is designed to elicit a strong and durable immune response, offering protection against current and future SARS-CoV-2 variants. Preliminary results from Phase 1 studies have been promising, showing the potential of the samRNA vaccine to induce high levels of neutralizing antibodies and broad T cell responses that last for up to 12 months (and probably longer.)

    The partnership with BARDA for the CORAL-BARDA Phase IIb study, now expected to commence in the third quarter of 2024, involves enrolling 10,000 subjects to evaluate the vaccine's safety, immunogenicity, and efficacy. This study not only showcases the confidence of the U.S. government in Gritstone's novel vaccine approach but also highlights the collaborative effort to accelerate the development of vaccines that could play a critical role in ending the pandemic and enhancing preparedness for future health crises.

    This strategic alliance with BARDA underscores the potential of Gritstone Bio's vaccine platforms not just in oncology but also in addressing infectious diseases, positioning the company at the forefront of efforts to create more effective and enduring solutions to global health challenges.
  8. forum rang 5 Piddy 25 februari 2024 19:59
    The Future of Immunotherapy: What's Next for Gritstone?

    The journey from understanding the intricacies of cancer and infectious diseases to harnessing the power of the immune system through cutting-edge technology is just beginning. The future of immunotherapy, particularly in the context of Gritstone's pioneering work, beckons with possibilities that could redefine our approach to some of the most challenging diseases of our time.

    The immediate future for Gritstone involves advancing their vaccine candidates through the rigorous phases of clinical trials, a critical step in translating groundbreaking scientific research into tangible treatments for patients. Success in these trials could not only validate the effectiveness of personalized cancer vaccines and innovative infectious disease treatments but also set a new standard for immunotherapy. As these trials progress, we can anticipate a wealth of data that will further refine our understanding of how best to mobilize the immune system in the fight against disease.

    Looking further ahead, the potential applications of Gritstone's technology extend beyond the current targets of cancer and infectious diseases. The principles underlying their AI-driven platforms could be adapted to tackle a broader spectrum of autoimmune diseases, genetic disorders, and other conditions where the immune system plays a pivotal role. The versatility of Gritstone's approach offers a glimpse into a future where personalized immunotherapy becomes a cornerstone of treatment across a wide array of diseases, tailored not just to the disease but to the individual patient's genetic makeup.

    Moreover, the integration of AI and machine learning in immunotherapy research is poised to accelerate the pace of discovery and development. As AI algorithms become more sophisticated and datasets grow richer, the predictive power of platforms like EDGE will only improve. This evolution promises to make the development of vaccines and therapies faster, more efficient, and more effective, potentially ushering in a new era of rapid response to emerging health threats.

    The future of immunotherapy, particularly through the lens of Gritstone Bio's work, is a vista of immense potential. As we stand on the cusp of this new frontier, the promise of a world where treatments are not just personalized but profoundly effective offers hope to millions. The path forward is paved with challenges, but the direction is clear: towards a healthier, more hopeful tomorrow, driven by the relentless pursuit of scientific excellence and the transformative power of AI in medicine.

    A Healthier Tomorrow Starts Today
    As we wrap up our exploration of Gritstone Bio's groundbreaking journey in personalized cancer vaccines and the broader implications of AI in healthcare, it's clear we stand at the cusp of a new era in medicine. The advancements we've discussed not only showcase the incredible potential of AI to transform healthcare but also highlight a future where treatments are not just reactive but proactive and personalized. This is a future where the battle against diseases like cancer and infectious diseases is fought with precision tools tailored to the individual's genetic makeup, offering hope for more effective and less invasive treatments.

    2024 price target: $15. !!!

    Gritstone Bio's work exemplifies the synergy between technology and medicine, a partnership that promises to unlock new possibilities in our fight against some of humanity's most persistent foes. The company's innovative approach—leveraging the EDGE platform to identify neoantigens for personalized immunotherapy—represents just the beginning of what's possible when we harness the power of AI in healthcare.

    Bron : www.griproom.com/fun/gritstone-bio-ed...
  10. NetNix 26 februari 2024 15:31
    Beste Piddy,

    Hartelijk dank voor de uitgebreide informatie over dit bedrijf!
    Ik ben een kleinschalige belegger, die af en toe ook eens naar Biotech kijkt. Ooit goed het deksel op mijn neus gekregen met Galapagos, dus daardoor wel wat voorzichtiger geworden.
    Gezien ik lerende ben, had ik nog even een vraag. Op De GIRO wordt dit aandeel bestempelt als een “koop” met een koersdoel van 10 dollar. Maar aan de cijfers zie ik dit niet terug. Is dit dan puur gebasseerd op het te verwachten nieuws (ervan uitgaande dat dit positief is)?

    Excuses voor enige onnozelheid.
  11. forum rang 5 Piddy 26 februari 2024 16:21
    Ja, alle mogelijke koersdoelen voor grts zijn momenteel louter gebaseerd op toekomstige verwachtingen.
    Als je geen aderlating wil kan je ook pas instappen net na de bekendmaking van positieve data.
    Of rustig hopen op een georkestreerde stoploss aanval net onder de $2.

    Zekerheden zijn er niet.
    Slechte data en dit duikt zeker onder $0,5

    Succes bij elke vorm van beslissing!
  13. forum rang 5 Piddy 27 februari 2024 22:10
    11% erbij na de vorige stijgingen.
    Het voelt goed maar de zenuwachtigheid neemt verhoudingsgewijs ook toe.
    Het zal ooit voor mij de derde aanval worden om door de $3 te stoten.
    Benieuwd naar meer.

    De apotheose zoals bij Viking doet natuurlijk dromen.
    Nogmaals gefeliciteerd met die opwaartse sprong daar.
  17. forum rang 5 Piddy 28 februari 2024 19:33
    quote:

    Piddy schreef op 28 februari 2024 10:14:

    YTD

    VKTX : 357%
    GRTS: 34%
    ARWR: 2%

    Believers kopen nu best ook Arrowhead bij.
    Louter op basis van hun tijdelijke prestaties.
    Door de grote van de pipeline van dit bedrijf kan een persbericht met goeie data ook een raket beweging maken.

    Ik blijf all in in Gritstone.
    .

    Wat ARWR betreft wel voltreffer ivm eigen melding.
    Benieuwd wat er daar (op)leeft.
  18. NetNix 28 februari 2024 21:09
    quote:

    Piddy schreef op 26 februari 2024 16:21:

    Ja, alle mogelijke koersdoelen voor grts zijn momenteel louter gebaseerd op toekomstige verwachtingen.
    Als je geen aderlating wil kan je ook pas instappen net na de bekendmaking van positieve data.
    Of rustig hopen op een georkestreerde stoploss aanval net onder de $2.

    Zekerheden zijn er niet.
    Slechte data en dit duikt zeker onder $0,5

    Succes bij elke vorm van beslissing!
    Dank voor de toelichting!
    Zal het aandeel zeker blijven volgen, en misschien binnenkort wel wat inkopen.

    Succes!
  20. forum rang 5 Piddy 29 februari 2024 09:29
    Laatste IPV-vaccinonderzoek, welke is dit?

    www.lji.org/news-events/news/post/a-s...

    Helaas worden immuuntherapieën doorgaans niet aanbevolen voor patiënten met immunologisch ‘koude’ tumoren. Hun tumoren lijken vooral op gezond weefsel, wat het voor het immuunsysteem moeilijk maakt om de tumoren te detecteren en ze te vernietigen.

    Wetenschappers van het San Diego Moores Cancer Center hebben monsters verstrekt van 13 patiënten met acht verschillende soorten gevorderde solide tumoren: microsatellietstabiele colorectale, neuro-endocriene pancreastumoren, galwegkanker, eierstokkanker, ductaal adenocarcinoom van de pancreas, blindedarmkanker, plaveiselcelcarcinoom van hoofd en nek en niercelmaligniteiten. Het is bekend dat deze vormen van kanker bijzonder moeilijk te behandelen zijn en doorgaans niet reageren op alleen checkpointremmers.

    De resultaten waren zeer bemoedigend. Alle dertien patiënten maakten al T-cellen die mutaties in hun eigen kankers konden herkennen. Deze T-cellen waren zeldzaam, maar ze waren duidelijk aanwezig.
290 Posts
Pagina: «« 1 ... 7 8 9 10 11 ... 15 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!